https://www.helioscardio.com/news daily 0.75 2025-01-29 https://www.helioscardio.com/news/helios-cardio-announces-first-patient-enrolled-in-fda-investigational-new-drug-ind-study-of-cardiamend-and-amiodarone-for-postoperative-atrial-fibrillation-prophylaxis monthly 0.5 2025-01-04 https://www.helioscardio.com/news/helios-cardio-and-shamrock-surgical-announce-distribution-partnership monthly 0.5 2023-04-12 https://www.helioscardio.com/news/helios-cardio-awarded-a-spot-on-fss-dapa-and-ecat-contracts monthly 0.5 2022-09-15 https://www.helioscardio.com/news/helios-cardio-announces-us-fda-510k-clearance-for-a-new-pericardial-and-epicardial-reconstruction-matrix monthly 0.5 2022-01-06 https://www.helioscardio.com/news/helios-labs monthly 0.5 2021-05-19 https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1620250930670-NIZLNWR5C9ZIW4ODBM2X/Helios+Cardio+Research.jpg News and Events - Helios cardio Moves to New Laboratories https://www.helioscardio.com/news/welcome monthly 0.5 2021-05-19 https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1614112622642-EKERIJRNC7192EN019NH/I24A6847.jpg News and Events - Welcome to helios cardio https://www.helioscardio.com/about-us daily 0.75 2024-01-12 https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618084921282-1FXMV47ITVN5DBGKIX66/Clay+Kaiser.png About Us Clayton Kaiser MD Chief Medical Officer Dr. Kaiser received an undergraduate degree in Biomedical Engineering from Duke University, an MD from Vanderbilt University Medical School, and did his residency in Cardiovascular Surgery at Stanford Hospital and Clinics. Dr. Kaiser is currently a Staff Surgeon at Ascension Saint Thomas Heart, Nashville. His clinical areas of interest are in adult cardiac surgery, aortic aneurysms, connective tissue diseases, aortic/mitral valve disease, and minimally invasive cardiac surgery. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618839122417-5BPKX62ARC8MBUWABSER/Yiannis+Monovoukas.png About Us - Yiannis Monovoukas PhD, MBA Yiannis Monovoukas PhD, MBA Founder and Chief Executive Officer Dr. Monovoukas is the former Chairman, President, and CEO of TEI Biosciences and TEI Medical, two regenerative medicine companies founded on technology generated at MIT. Both companies were sold to Integra LifeSciences in 2015 for more than $300 million. Dr. Monovoukas holds a BS degree from Columbia University and MS and PhD degrees from Stanford University, all in chemical engineering, as well as an MBA from the Harvard Business School. Dr. Monovoukas was winner of the prestigious Ernst & Young Entrepreneur Of The Year® 2011 Award for New England in Life Sciences, and was a 2011 Life Sciences US National Finalist. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618839137307-WDD1NC1ECWERVG5J1SUI/Peter+Jackson.png About Us - Peter Jackson PhD Peter Jackson PhD Chief Commercial Officer With over 25 years of experience in R&D, business development and commercial leadership, Dr. Jackson has a unique set of skills to transition transformative medical technologies from laboratory to clinical and market success. Dr. Jackson has broad international experience having worked in the US, UK, France, The Netherlands, and Switzerland. Dr. Jackson holds a 1st class degree and PhD in chemistry from the Universities of Cardiff and Swansea, UK. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618839152844-5Q0DYIT6ZT0FU1UQ4AHN/Kevin+Cornwell.png About Us Kevin Cornwell PhD Chief Scientific Officer Dr. Cornwell is a recognized expert in Biomaterials & Tissue Engineering with 20 years of research and development into biopolymers and ECM biomaterials. He received a PhD from a joint WPI and UMASS Medical School program in Biomedical Engineering and Medical Physics. Kevin formerly held positions at TEI Biosciences and Integra LifeSciences where he worked closely with clinicians to develop and commercialize medical devices for a wide range of surgical applications including wound healing, general surgery, and reconstructive plastic surgery. https://www.helioscardio.com/products daily 0.75 2022-11-26 https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618858513957-E7MDETCOT1CWGJMH7Q1P/CardiaMend+incorporation.png CardiaMend - Pericardial repair in a large animal model A 3-month study in a large animal model exhibiting both pericardial and epicardial defects that had been repaired with CardiaMend™ showed: No scarring or inflammation associated with CardiaMend™ Pericardial repair showed no adhesions onto the epicardium Remodeling of CardiaMend™ into native tissue Neo-vascularization within remodeled tissue showing excellent tissue viability https://www.helioscardio.com/careers daily 0.75 2025-01-01 https://www.helioscardio.com/home daily 1.0 2023-04-04 https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/f1e6adec-7346-4517-a516-3c17aa7a40c9/Tissue+Scaffold.png https://www.helioscardio.com/technology daily 0.75 2022-11-26 https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618612420572-YSG1Z3JL3SO6FRATFVNM/EBM+Collagen+Type+III.png Technology - Harnessing the power of collagen type III f-EBM is the only biologic matrix containing abundant levels of collagen Type III. Collagen Type III is involved in “scarless healing” observed in fetal and neonatal mammals. Implanted fetal collagen matrix, provides signals to a variety of cell surface receptors stimulating tissue regeneration and attenuating fibrosis. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618428520006-4UNK5TPSGUBBBQ3S8XNR/EBM+Usability.png Technology - exceptional Surgical Usability f-EBM is supplied dry but hydrates in room temperature saline in only 1-2 minutes with no disruption to standard surgical protocols. Once hydrated, f-EBM exhibits excellent handling characteristics, exhibiting flexibility and conformability without risking rippling during suturing. f-EBM’s class-leading suture retention strength provides surgeons a matrix they love to work with. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618433771577-26GBIEINIAF9FYQW5OVZ/EBM+purity.png Technology - exceptional Purity Our patented tissue engineering processes produce an exceptionally pure collagen scaffold, free of non collagen proteins, lipids, growth factors, or other inflammatory cellular remnants. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618426582450-09AKJP598F2ORCSO3LCH/EBM+Angiogenesis.png Technology - Angiogenesis and tissue regeneration As a natural acellular scaffold with Type III collagen regenerative signalling, f-EBM displays both the ability to become repopulated with host cells, and to stimulate angiogenesis, a prerequisite for maturation of the matrix into functional host tissue (refs. 4, 5). https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618612904777-K27K2E05C90CSWUP8JQB/EBM+porosity.png Technology - high absorbance capacity for pharmacotherapies Due to the sponge-like nature of f-EBM, large quantities of drugs can be formulated within the 3-dimensional structure of the scaffold. Combining the natural strength and tissue friendliness of -fEBM together with the high loading capacity for a variety of active pharmaceutical ingredients, f-EBM serves as an ideal matrix for research-based local delivery of drugs to tissues. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618844360291-1DH59PULBZXNWIZ8BTTD/EBM+range.png Technology - unmatched range of thicknesses Different surgical situations can require different material thicknesses depending the requirements for ultimate tensile strength, anatomical location, and conformability. f-EBM provides surgeons with a market leading choice of formats ranging from less than 0.5 mm to more than 4 mm in thickness. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618444342489-PODO0UKSJGAD50SPV572/EBM+strength.png Technology - Strength without crosslinking With a 3-dimensional network of collagen fibers, dermis is extremely strong, capable of withstanding both elevated tearing and suture stresses. In fact, bovine dermis is one of the strongest (refs. 1, 2, 3), soft biomaterials known, providing mechanical strength without employing crosslinking technologies. Although strong, f-EBM is highly conformable and has excellent surgical handling characteristics. https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/1618612789433-XI56BX341FYCZ3RJ2VWV/EBM+stem+cells.png Technology - An ideal matrix for stem cell research The cell-friendly environment of a non-crosslinked, 3-dimensional scaffold, combined with the regenerative signalling of collagen Type III, provides an ideal matrix for stem cell research. Furthermore, the natural porosity and thicknesses of fetal bovine dermis provides a large cell loading capacity. Previous work (refs. 6, 7) has shown that human mesenchymal cells can proliferate within the f-EBM matrix and migrate to surrounding myocardial tissue. This opens up many possibilities for treating intractable diseases such as heart failure. https://www.helioscardio.com/rsvp-1 daily 0.75 2025-02-04 https://images.squarespace-cdn.com/content/v1/5e5cd66d1dd62e116f3154b7/799d1c74-66e8-4f73-a1b8-06537a94edb6/Webinar+invitation+%281%29.png